• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".

作者信息

Gandjour Afschin

机构信息

Frankfurt School of Finance and Management, Frankfurt, Germany,

出版信息

Pharmacoeconomics. 2014 Dec;32(12):1245-6. doi: 10.1007/s40273-014-0221-3.

DOI:10.1007/s40273-014-0221-3
PMID:25253682
Abstract
摘要

相似文献

1
Comment on: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".关于《中低收入国家当前的成本效益阈值是否有用？疫苗领域的实例》的评论
Pharmacoeconomics. 2014 Dec;32(12):1245-6. doi: 10.1007/s40273-014-0221-3.
2
Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".作者对甘乔尔的回复：“当前中低收入国家的成本效益阈值有用吗？来自疫苗领域的例子”。
Pharmacoeconomics. 2014 Dec;32(12):1247. doi: 10.1007/s40273-014-0232-0.
3
Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines.当前中低收入国家的成本效益阈值有用吗？来自疫苗领域的例子。
Pharmacoeconomics. 2014 Jun;32(6):525-31. doi: 10.1007/s40273-014-0162-x.
4
[Criteria for introducing new vaccines into the vaccination calendar].[将新疫苗纳入疫苗接种计划的标准]
Rev Esp Quimioter. 2007 Mar;20(1):131-42.
5
Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.轮状病毒疫苗 RIX4414（罗特律®）：在发展中国家预防轮状病毒胃肠炎的药物经济学评价。
Pharmacoeconomics. 2011 Nov;29(11):989-1009. doi: 10.2165/11207210-000000000-00000.
6
WHO advisory committee on Immunization and Vaccine related Implementation Research (IVIR, formerly QUIVER): executive summary report of 6th meeting.世界卫生组织免疫与疫苗相关实施研究咨询委员会（IVIR，前身为QUIVER）：第六次会议执行摘要报告
Wkly Epidemiol Rec. 2013 Jan 25;88(4):43-6.
7
GAVI gears up for record replenishment.全球疫苗免疫联盟（GAVI）为创纪录的资金补充做准备。
Lancet. 2014 Jul 19;384(9939):219-20. doi: 10.1016/s0140-6736(14)61196-x.
8
Bioterrorism: what level is the threat and are vaccines the answer?生物恐怖主义：威胁程度如何，疫苗能否应对？
Expert Rev Vaccines. 2004 Oct;3(5):493-5. doi: 10.1586/14760584.3.5.493.
9
Status of HPV vaccine introduction and barriers to country uptake.HPV 疫苗接种状况及国家引入的障碍。
Vaccine. 2018 Aug 6;36(32 Pt A):4761-4767. doi: 10.1016/j.vaccine.2018.02.003. Epub 2018 Mar 23.
10
Wyeth responds to criticism.惠氏回应批评。
Md Med. 2005 Autumn;6(4):5, 7-8; author reply 8.

引用本文的文献

1
Comment on: "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy".评论：《健康决策：迈向医疗保健政策中的不确定性容忍度》
Pharmacoeconomics. 2015 Sep;33(9):981-2. doi: 10.1007/s40273-015-0317-4.
2
Authors' reply to Gandjour: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".作者对甘乔尔的回复：“当前中低收入国家的成本效益阈值有用吗？来自疫苗领域的例子”。
Pharmacoeconomics. 2014 Dec;32(12):1247. doi: 10.1007/s40273-014-0232-0.

本文引用的文献

1
Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines.当前中低收入国家的成本效益阈值有用吗？来自疫苗领域的例子。
Pharmacoeconomics. 2014 Jun;32(6):525-31. doi: 10.1007/s40273-014-0162-x.
2
Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule.药品定价与医疗支出控制：比例决策规则与每质量调整生命年成本规则的比较
Int J Health Plann Manage. 2015 Oct-Dec;30(4):395-402. doi: 10.1002/hpm.2247. Epub 2014 May 1.
3
The German method for setting ceiling prices for drugs: in some cases less data are required.
德国药品最高限价设定方法：某些情况下所需数据更少。
Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):403-9. doi: 10.1586/erp.11.45.
4
Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules.德国药品定价上限设定决策规则：与其他决策规则的比较分析。
Appl Health Econ Health Policy. 2011 Mar 1;9(2):65-71. doi: 10.2165/11586640-000000000-00000.
5
[Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].[医疗保健经济评估方法工作组（AG MEG）对IQWiG《德国法定医疗保健系统中效益与成本关系评估方法》指南草案的评论]
Gesundheitswesen. 2008 Jun;70(6):e1-16. doi: 10.1055/s-2008-1077059.
6
Cost-effectiveness analysis and innovation.成本效益分析与创新
J Health Econ. 2008 Sep;27(5):1224-36. doi: 10.1016/j.jhealeco.2008.05.010. Epub 2008 Jun 5.
7
Demography. Broken limits to life expectancy.人口统计学。预期寿命突破极限。
Science. 2002 May 10;296(5570):1029-31. doi: 10.1126/science.1069675.